Peer-reviewed veterinary case report
p53 protein patterns linked to vaccine sarcoma outcomes in cats
By Hershey, A E et al.·Published in Veterinary pathology·2005·Department of Medical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Aberrant p53 expression in feline vaccine-associated sarcomas and correlation with prognosis.
- Species:
- cat
Plain-English summary
A study looked at 80 cats with vaccine-associated sarcomas, which are tumors that can develop at vaccination sites. Researchers found that a high percentage of these tumors showed abnormal levels of a protein called p53, which is important for controlling cell growth. Cats with tumors showing a specific pattern of p53 were more likely to have their tumors come back quickly after treatment, although this did not affect how long they lived overall. This information could help vets predict how aggressive the tumor might be and guide future treatment options.
People also search for: cat vaccine-associated sarcoma prognosis · feline tumor treatment options · p53 protein in cat tumors
Abstract
Eighty spontaneously occurring feline vaccine-associated sarcomas (VAS) were evaluated to determine the immunohistochemical expression of the tumor suppressor gene p53. Sixty-five of 80 VAS (81%) exhibited positive immunoreactivity with Mab240, a murine monoclonal antibody that specifically recognizes mutated p53. Only 44 of 81 tumors (55%) were positive with rabbit polyclonal antibody CM-1. CM-1 often yielded nonspecific staining of nonneoplastic tissues. Nonspecific staining was greatly reduced or absent with Mab240. Cytoplasmic staining for p53 was a consistent pattern of VAS, occurring in 44% of tumors evaluated. Cats with tumors that exhibited cytoplasmic p53 had significantly shorter time to tumor recurrence compared to those cats with tumors that exhibited nuclear p53 staining (P = 0.0284), but no significant difference in survival outcome was observed. Immunohistochemical detection of p53 offers a prognostic tool for VAS, and, because abnormal p53 expression appears to be a common feature of feline VAS, molecular targeting of mutant p53, may offer a promising new therapeutic opportunity for this cancer.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16301577/